Estimating the Number of Chinese Cancer Patients Eligible for and Benefit from Immune Checkpoint Inhibitors

Overview

Journal Front Med

Specialty General Medicine

Date 2022 Jul 1

PMID 35776405

Authors

Kaili Yang

Jiarui Li

Lin Zhao

Zhao Sun

Chunmei Bai

Affiliations

Soon will be listed here.

Abstract

The total number of cancer patients who are eligible for and will benefit from immune checkpoint inhibitors (ICIs) in China has not been quantified. This cross-sectional study was conducted to estimate the number of Chinese cancer patients with eligibility and response to ICIs based on the 2015 Chinese cancer statistics and the immune checkpoint inhibitor clinical practice guideline of the Chinese Society of Clinical Oncology. A total of 11 ICIs were recommended for 17 cancer types. The estimated number of eligible patients annually was 1 290 156 (55.18%), which included 888 738 males (60.05%) and 400 468 females (46.67%). The estimated number of responders annually was 448 972 (19.20%), which included 309 023 males (20.88%) and 139 764 females (16.29%). Gastric cancer (n=291 000, 12.45%), non-small-cell lung cancer (n=289 629, 12.39%), and hepatocellular carcinoma (n=277 100, 11.85%) were the top three cancer types with the highest number of eligible patients. Non-small-cell lung cancer (n=180 022, 7.70%), hepatocellular carcinoma (n=75 648, 3.24%), and small-cell lung cancer (n=64 362, 2.75%) were the top three cancer types with the highest number of responders. In conclusion, ICIs provide considerable benefit in Chinese cancer patients under optimal estimation.

Citing Articles

The causal relationship between immune cells and hepatocellular carcinoma: a Mendelian randomization (MR).

Nov P, Zhang Y, Wang D, Sou S, Touch S, Kouy S Ecancermedicalscience. 2025; 18():1794.

PMID: 39816386 PMC: 11735144. DOI: 10.3332/ecancer.2024.1794.

How many Italian cancer patients are eligible for, and may respond to, Italian Medicines Agency-approved immune checkpoint inhibitors?.

Crocetti E, Ravaioli A, Falcini F, Vattiato R, Mancini S, Baldacchini F Tumori. 2024; 110(2):109-115.

PMID: 38372036 PMC: 11005312. DOI: 10.1177/03008916241229649.

Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic challenges.

Jiang Z, Zheng X, Li M, Liu M Front Med. 2023; 17(6):1135-1169.

PMID: 38151666 DOI: 10.1007/s11684-023-1050-6.

Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target.

Zhang M, Liu J, Xia Q Exp Hematol Oncol. 2023; 12(1):84.

PMID: 37770953 PMC: 10537950. DOI: 10.1186/s40164-023-00442-x.

Identifying the oncogenic roles of FAP in human cancers based on systematic analysis.

Ma C, Xi S, Sun H, Zhang M, Pei Y Aging (Albany NY). 2023; 15(14):7056-7083.

PMID: 37490719 PMC: 10415543. DOI: 10.18632/aging.204892.

References

Peng L, Qin B, Xiao K, Xu S, Yang J, Zang Y . A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncoimmunology. 2020; 9(1):1781333. PMC: 7458616. DOI: 10.1080/2162402X.2020.1781333. View

Zeng H, Chen W, Zheng R, Zhang S, Ji J, Zou X . Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018; 6(5):e555-e567. DOI: 10.1016/S2214-109X(18)30127-X. View

Vandenbroucke J, von Elm E, Altman D, Gotzsche P, Mulrow C, Pocock S . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 4(10):e297. PMC: 2020496. DOI: 10.1371/journal.pmed.0040297. View

Benson A, Venook A, Al-Hawary M, Arain M, Chen Y, Ciombor K . Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(3):329-359. DOI: 10.6004/jnccn.2021.0012. View

Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349):409-413. PMC: 5576142. DOI: 10.1126/science.aan6733. View

Haslam A, Prasad V . Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. JAMA Netw Open. 2019; 2(5):e192535. PMC: 6503493. DOI: 10.1001/jamanetworkopen.2019.2535. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Fan L, Strasser-Weippl K, Li J, St Louis J, Finkelstein D, Yu K . Breast cancer in China. Lancet Oncol. 2014; 15(7):e279-89. DOI: 10.1016/S1470-2045(13)70567-9. View

Schmid P, Adams S, Rugo H, Schneeweiss A, Barrios C, Iwata H . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018; 379(22):2108-2121. DOI: 10.1056/NEJMoa1809615. View

10.

Stovgaard E, Dyhl-Polk A, Roslind A, Balslev E, Nielsen D . PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review. Breast Cancer Res Treat. 2019; 174(3):571-584. DOI: 10.1007/s10549-019-05130-1. View

11.

Foulkes W, Smith I, Reis-Filho J . Triple-negative breast cancer. N Engl J Med. 2010; 363(20):1938-48. DOI: 10.1056/NEJMra1001389. View

12.

Jiang X, Tang H, Chen T . Epidemiology of gynecologic cancers in China. J Gynecol Oncol. 2017; 29(1):e7. PMC: 5709533. DOI: 10.3802/jgo.2018.29.e7. View

13.

Verma V, Sprave T, Haque W, Simone 2nd C, Chang J, Welsh J . A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018; 6(1):128. PMC: 6251215. DOI: 10.1186/s40425-018-0442-7. View

14.

Bai R, Lv Z, Xu D, Cui J . Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020; 8:34. PMC: 7450548. DOI: 10.1186/s40364-020-00209-0. View

15.

Nabet B, Esfahani M, Moding E, Hamilton E, Chabon J, Rizvi H . Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020; 183(2):363-376.e13. PMC: 7572899. DOI: 10.1016/j.cell.2020.09.001. View

16.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View

17.

Twomey J, Zhang B . Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. AAPS J. 2021; 23(2):39. PMC: 7937597. DOI: 10.1208/s12248-021-00574-0. View

18.

Xie C, Duffy A, Brar G, Fioravanti S, Mabry-Hrones D, Walker M . Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020; 26(10):2318-2326. PMC: 8284008. DOI: 10.1158/1078-0432.CCR-19-3624. View

19.

Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S . Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019; 4(8):611-621. DOI: 10.1016/S2468-1253(19)30086-X. View

20.

Lukas R, Rodon J, Becker K, Wong E, Shih K, Touat M . Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma. J Neurooncol. 2018; 140(2):317-328. DOI: 10.1007/s11060-018-2955-9. View